Compare BGT & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGT | CVRX |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.3M | 171.7M |
| IPO Year | 2004 | 2021 |
| Metric | BGT | CVRX |
|---|---|---|
| Price | $10.75 | $9.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.20 |
| AVG Volume (30 Days) | 134.3K | ★ 183.2K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $56,651,000.00 |
| Revenue This Year | N/A | $16.65 |
| Revenue Next Year | N/A | $18.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.45 |
| 52 Week Low | $10.21 | $4.37 |
| 52 Week High | $12.76 | $12.67 |
| Indicator | BGT | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 59.60 |
| Support Level | $10.59 | $8.42 |
| Resistance Level | $10.85 | $10.39 |
| Average True Range (ATR) | 0.16 | 0.70 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 87.30 | 70.44 |
Blackrock Floating Rate Income Trust is a diversified closed-end management investment company. Its investment objective is to provide a high level of current income. The company, as a secondary objective, also focuses on preservation of capital to the extent consistent with its primary objective of high current income. The Trust seeks to achieve its investment objectives by investing in worl-wide portfolio of floating rate securities, including investing a substantial amount in U.S. and non-U.S. senior secured floating rate loans (Senior Loans), made to corporate and other business entities.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.